Publication Name	World Journal of Hepatology
Manuscript ID	21590
Country	United States

Received	2015-07-21 08:27
Peer-Review Started	2015-07-24 15:46
To Make the First Decision	2015-08-16 14:55
Return for Revision	2015-10-22 10:58
Revised	2015-10-24 00:00
Second Decision	2015-11-09 11:05
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-11-25 16:11
Articles in Press	2015-11-25 16:11
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-11-27 14:50
Publish the Manuscript Online	2015-12-04 15:24

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Update on hepatitis C: Direct-acting antivirals
Manuscript Source	Invited Manuscript
All Author List	Leon L Seifert, Ryan B Perumpail and Aijaz Ahmed
Funding Agency and Grant Number
Corresponding Author	Aijaz Ahmed, MD, Associate Professor of Medicine, Medical Director Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 750 Welch Road, Suite 210, Stanford, CA 94305, United States. aijazahmed@stanford.edu
Key Words	Hepatitis C virus; Direct-acting antivirals; Sustained virologic response; Management; Treatment
Core Tip	Recently, several direct-acting antivirals (DAAs) have been approved for treatment of hepatitis C virus (HCV)-infected patients and to help combat the virus. These drugs have revolutionized the management of HCV as all-oral regimens with favorable side effect profiles and superior rates of sustained virological response. Emerging real-world data are demonstrating results comparable to registration trials for DAA agents. Suddenly, the potential for eradicating HCV is on the horizon.
Publish Date	2015-12-04 15:24
Citation	Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015; 7(28): 2829-2833
URL	http://www.wjgnet.com/1948-5182/full/v7/i28/2829.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i28.2829

Full Article (PDF)	WJH-7-2829.pdf
Full Article (Word)	WJH-7-2829.doc
Manuscript File	21590-Review.docx
Answering Reviewers	21590-Answering reviewers.pdf
Audio Core Tip	21590-Audio core tip.wma
Conflict-of-Interest Disclosure Form	21590-Conflict-of-interest statement.pdf
Copyright License Agreement	21590-Copyright assignment.pdf
Peer-review Report	21590-Peer-review(s).pdf
Scientific Misconduct Check	21590-Scientific misconduct check.pdf
Scientific Editor Work List	21590-Scientific editor work list.pdf